Clinical trials: Inflammatory Disorder
Breast Cancer
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01796197
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Septic Shock, Fluid Therapy
Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock
The purpose of the study is to determine if a protocol that assesses patients' daily fluid intake and output can decrease the overall amount of fluid patients receive during the first five days in the ICU.
- Conditions
- Septic Shock, Fluid Therapy, Hypotension
- Trial name
- NCT02473718
- Testing
- Fluid minimization protocol, Ultrasound
- Volunteers
- 82 people
- Sponsor
- Washington University School of Medicine
Inflammatory Bowel Disease, Crohn's Disease
Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560)
This observational study will evaluate the social cost and quality of life of participants who have had Crohn's Disease for at least 6 months and have active disease despite drug therapy.
- Trial name
- COSMO (NCT00723840)
- Testing
- Observational Studies: participants treated according to the real clinical practice.
- Volunteers
- 245 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Randomized, double-blind, comparative study versus placebo performed in patients from studies CB-01-02/01 (NCT00679432), CB-01-02/02 (NCT00679380), or CB-01-02/06 (NCT01100112) who achieved ulcerative colitis disease activity…
- Trial name
- NCT00801723
- Testing
- Budesonide MMX 6 mg Tablet
- Where
- 58 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Bausch Health Americas, Inc.
Crohn's Disease
Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
Primary objective: Assessment of the efficacy of EryDex vs PLACEBO in maintaining patients with steroid-dependent Crohn's disease in clinical remission throughout 12 months without oral steroids. Secondary objectives: 1.
- Trial name
- Crodex (NCT01277289)
- Testing
- Dexamethasone
- Where
- 8 sites in Italy, Romania and 1 more
- Volunteers
- 51 people
- Sponsor
- Quince Therapeutics S.p.A.
Crohn's Disease
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active CD who achieved clinical response following administration…
- Trial name
- NCT02611817
- Testing
- Vedolizumab SC 108 mg, Vedolizumab IV 300 mg
- Where
- 194 sites in United States, Australia and 28 more
- Volunteers
- 644 people
- Sponsor
- Takeda
Polymyositis, Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients…
- Trial name
- PRESIDIO (NCT04033926)
- Testing
- KZR-616
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 25 people
- Sponsor
- Kezar Life Sciences, Inc.
Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types…
- Conditions
- Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia
- Trial name
- NCT04882085
- Testing
- Zavicefta, Ceftazidime-Avibactam, Best Available Treatment
- Where
- 37 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Psoriasis, Atherosclerotic Cardiovascular Disease
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
Background: Psoriasis causes chronic inflammation in the body. Researchers want to see if a kind of vitamin B3 dietary supplement can help. This might lead to more treatment options.
- Conditions
- Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia
- Trial name
- NCT04271735
- Testing
- Niagen
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis…
- Trial name
- NCT02365649
- Testing
- ABT-494
- Volunteers
- 220 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis
The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in adults with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with…
- Trial name
- BALANCE-EXTEND (NCT02049138)
- Testing
- Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13)
- Where
- 124 sites in United States, Belgium and 16 more
- Volunteers
- 493 people
- Sponsor
- AbbVie
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
The purpose of this study is to evaluate the efficacy and safety of ontamalimab as maintenance treatment in participants with moderate to severe Crohn's disease (CD).
- Trial name
- CARMEN CD 307 (NCT03627091)
- Testing
- Ontamalimab
- Where
- 281 sites in United States, Argentina and 32 more
- Volunteers
- 40 people
- Sponsor
- Shire
Crohn's Disease, IBD
Open-label Extension Study of Brazikumab in Crohn's Disease
The purpose of Study D5271C00002 (Legacy #3150-303-008) is to permit participants in D5271C00001 (Legacy #3150-301-008) to receive open-label brazikumab in Study D5271C00002 (Legacy #3150-303-008).
- Trial name
- INTREPID OLE (NCT03961815)
- Testing
- Brazikumab Induction Dose, Brazikumab Maintenance Dose
- Where
- 15 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Colitis, Ulcerative
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
The purpose of this study is to investigate the efficacy and safety of vedolizumab intravenous (IV) dose optimization on mucosal healing compared with the standard vedolizumab IV dosing regimen over a 30 week treatment period in…
- Trial name
- ENTERPRET (NCT03029143)
- Testing
- Vedolizumab IV
- Where
- 49 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Takeda
Advanced Cancer, Hematologic Malignancy
Fatigue in Emergency Center Patients
1. To describe fatigue severity and its related symptom clusters in cancer patients who are seeking emergency care for fever, pain, shortness of breath, or cancer therapy-related gastrointestinal toxicities. 2.
- Conditions
- Advanced Cancer, Hematologic Malignancy, Fatigue
- Trial name
- NCT00504985
- Testing
- Surveys
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Severe Sepsis, Acute Respiratory Failure
Effect of Different Electric Muscle Stimulation in Patients With Severe Sepsis and Respiratory Failure
Rationale : Electric muscle stimulation reduced critical-illness related weakness in patients with severe sepsis and septic shock. But optimal protocol of the stimulation in unknown.
- Conditions
- Severe Sepsis, Acute Respiratory Failure, Muscle Hypotonia, Inflammation
- Trial name
- NCT01895647
- Testing
- EMS
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Mackay Memorial Hospital
Continuous Glucose Monitoring, Oral Glucose Tolerance
Non-Nutritive Sweetener Consumption and Glucose Homeostasis in Older Adults With Prediabetes
Animal and observational research in humans suggest that specific types of non-nutritive sweeteners (NNS) may impair glycemic control.
- Conditions
- Continuous Glucose Monitoring, Oral Glucose Tolerance, Insulin Sensitivity, Inflammatory Markers
- Trial name
- NCT05337098
- Testing
- Non-Nutritive Sweetener Intake and impact on glucose homeostasis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Polytechnic Institute and State University
Crohn's Disease
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
- Trial name
- NCT00724958
- Testing
- Infliximab
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
The purpose of this study is to evaluate the efficacy and safety of ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 305 (NCT03559517)
- Testing
- Ontamalimab
- Where
- 138 sites in United States, Australia and 14 more
- Volunteers
- 30 people
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.